Overview

Also Known As:B6 TRAMP mice

These mice harbor the Transgenic Adenocarcinoma of the Mouse Prostate (TRAMP); PB-Tag Line 8247 transgene. Mice hemizygous for the TRAMP transgene develop progressive forms of prostate cancer with distant site metastasis and exhibit various forms of disease from mild intraepithelial hyperplasia to large multinodular malignant neoplasia.

Donating Investigator

Dr. Norman M. Greenberg, Pfizer Global Research and Development

Genetic overview

Genetic Background	Generation
	N?+12pN32 (2021-01-05 00:00:00)

Tg(TRAMP)8247Ng

Allele Type
Transgenic (Inserted expressed sequence)

View Genetics

Research Applications

Reproductive Biology Research
Cancer Research

View All Research Applications

Base Price

Starting at:

$255.00 Domestic price for female 4-week

281.22 Domestic price for breeder pair

View Price List

Details

Detailed Description

These mice harbor the Transgenic Adenocarcinoma of the Mouse Prostate (TRAMP); PB-Tag Line 8247 transgene. Mice hemizygous for the TRAMP transgene develop progressive forms of prostate cancer with distant site metastasis and exhibit various forms of disease from mild intraepithelial hyperplasia to large multinodular malignant neoplasia. TRAMP hemizygotes can exhibit prostatic epithelial neoplasia (PIN) by 12 weeks of age. Tumors, appearing as well differentiated adenocarcinoma, can arise by 24 weeks of age, mostly in the dorsal and lateral lobes of the prostate. By 30 weeks of age, most hemizygous mice will display evidence of metastatic spread to the lymph nodes and/or lungs, phylloides appearance of some tumors, and seminal vesicle invasion. Tumors exhibit elevated levels of nuclear TRP53 and decreased androgen receptor expression. Note that pure C57BL/6 TRAMP hemizygotes may live to 52 weeks of age or longer.

Development

These TRAMP transgenic mice were developed in the laboratory of Dr. Norman M. Greenberg at Baylor College of Medicine. The TRAMP (Transgenic Adenocarcinoma of Mouse Prostate) transgenic construct was designed with simian virus 40 (SV40) early genes (large and small tumor antigens, Tag) under the control of the rat probasin promoter. The founder mouse (line 8247) described in the primary publication is one that developed a large prostate tumor by 10 weeks of age and was generated on a C57BL/6 background. The donating investigator maintains the strain by breeding hemizygous females with C57BL/6 males. The strain has been backcrossed to C57BL/6 for 20+ generations.

In 2019, sequencing performed by The Jackson Laboratory discovered that greater than 20 copies of the Tg(TRAMP)8247Ng transgene (hemizygous) integrated on chromosome 16 (~18,993,000-19,272,880; mouse mm10). The region surrounding the integration site has duplicated. Currently, there are no genes annotated in this region.

Expression Data

Expressed Gene	TAg, SV40 large T-antigen, SV40
Site of Expression

Control Suggestions

Noncarrier
000664 C57BL/6J

Additional Information

Considerations for Choosing Controls

Selected References

Greenberg NM; DeMayo F; Finegold MJ; Medina D; Tilley WD; Aspinall JO; Cunha GR; Donjacour AA; Matusik RJ; Rosen JM. 1995. Prostate cancer in a transgenic mouse. Proc Natl Acad Sci U S A 92(8):3439-43PubMed: 7724580 MGI: J:65303
Huss WJ; Maddison LA; Greenberg NM. 2001. Autochthonous mouse models for prostate cancer: past, present and future. Semin Cancer Biol 11(3):245-60PubMed: 11407949 MGI: J:78291

View All References

Genetics

Tg(TRAMP)8247Ng

Allele Symbol: Tg(TRAMP)8247Ng

Allele Name	transgene insertion 8247, Norman M Greenberg
Allele Type	Transgenic (Inserted expressed sequence)
Allele Synonym(s)	PB-Tag; probasin/Tag; Tg(Pbsn-TAg)8247Ng; TRAMP
Gene Symbol and Name	Tg(TRAMP)8247Ng, transgene insertion 8247, Norman M Greenberg
Gene Synonym(s)
Promoter	Pb, probasin, rat
Expressed Gene	TAg, SV40 large T-antigen, SV40
Strain of Origin	C57BL/6
Chromosome	16
General Note	TRAMP stands for TRansgenic Adenocarcinoma Mouse Prostate. Lines 5666 and 8079 were also produced. Transgenic mice on a C57BL6 background develop progressive forms of prostate cancer with distant site metastasis. Forms of disease range from mild intraepithelial hyperplasia to large multinodular malignant neoplasia. Tumors are detected in the prostate as early as 10 weeks of age. The tumors have elevated levels of nuclear TRP53 and decreased androgen receptor expression.
Molecular Note	Expression of the SV40 early region tumor antigen was driven in mouse prostate epithelium via a rat probasin promoter region fragment (-426/+28 bp). Sequencing identified greater than 20 copies of the Tg(TRAMP)8247Ng transgene (hemizygous) integrated on chromosome 16 (~18,993,000-19,272,880; mouse mm10). The region surrounding the integration site has duplicated. Currently, there are no genes annotated in this region.
Mutations Made By	Dr. Norman Greenberg, Pfizer Global Research and Development

Disease/Phenotype

Disease Terms

Characteristics of this human disease are associated with transgenes and other mutation types in the mouse.

prostate cancer

Research Areas By Phenotype

This mouse can be used to support research in many areas including:

Reproductive Biology Research
- Prostate Tumors
Cancer Research
- Increased Tumor Incidence
  - Prostate Tumors

Mammalian Phenotype Terms by Genotype

The following phenotype information is associated with a similar, but not exact match to this JAX^® Mice strain

Genotype: Tg(TRAMP)8247Ng/0
involves: 129/Sv * C57BL/6

endocrine/exocrine gland phenotype

increased prostate gland adenocarcinoma incidence

increased prostate intraepithelial neoplasia incidence
- in lesions, basal cells are not disorganized in contrast to Tg(Pbsn-ERG*)1Vv mice at 13 weeks

increased prostate gland tumor incidence
- intraepithelial neoplasia and adenocarcinomas at different stages of differentiation are observed in the prostrate
- mice are moribund with prostrate tumors on average at 31.4 weeks of age

reproductive system phenotype

increased prostate gland tumor incidence
- intraepithelial neoplasia and adenocarcinomas at different stages of differentiation are observed in the prostrate
- mice are moribund with prostrate tumors on average at 31.4 weeks of age

increased prostate gland adenocarcinoma incidence

increased prostate intraepithelial neoplasia incidence
- in lesions, basal cells are not disorganized in contrast to Tg(Pbsn-ERG*)1Vv mice at 13 weeks

neoplasm

increased prostate gland tumor incidence
- intraepithelial neoplasia and adenocarcinomas at different stages of differentiation are observed in the prostrate
- mice are moribund with prostrate tumors on average at 31.4 weeks of age

increased prostate intraepithelial neoplasia incidence
- in lesions, basal cells are not disorganized in contrast to Tg(Pbsn-ERG*)1Vv mice at 13 weeks

increased prostate gland adenocarcinoma incidence

Genotype: Tg(TRAMP)8247Ng/0
involves: C3H * C57BL/6

endocrine/exocrine gland phenotype

increased prostate gland adenocarcinoma incidence

increased prostate gland weight
- prostates weigh an average of >6g, while in transgenic mice expressing the Tg(ACTB-SAC/EGFP)35Rang transgene, most (78.5%) prostate glands weigh <2g and remaining 21.5% weigh between 2 and 3 grams

increased prostate gland tumor incidence
- majority (62.5-83.3%) of mice develop high-grade prostatic intraepithelial neoplasia by 3 months of age and 12-16% of animals show adenocarcinoma of the prostate; by 6 months, all mice develop adenocarcinoma of the prostate

increased prostate intraepithelial neoplasia incidence

neoplasm

increased prostate gland adenocarcinoma incidence

increased prostate intraepithelial neoplasia incidence

increased prostate gland tumor incidence
- majority (62.5-83.3%) of mice develop high-grade prostatic intraepithelial neoplasia by 3 months of age and 12-16% of animals show adenocarcinoma of the prostate; by 6 months, all mice develop adenocarcinoma of the prostate

reproductive system phenotype

increased prostate gland adenocarcinoma incidence

increased prostate gland tumor incidence
- majority (62.5-83.3%) of mice develop high-grade prostatic intraepithelial neoplasia by 3 months of age and 12-16% of animals show adenocarcinoma of the prostate; by 6 months, all mice develop adenocarcinoma of the prostate

increased prostate gland weight
- prostates weigh an average of >6g, while in transgenic mice expressing the Tg(ACTB-SAC/EGFP)35Rang transgene, most (78.5%) prostate glands weigh <2g and remaining 21.5% weigh between 2 and 3 grams

increased prostate intraepithelial neoplasia incidence

Genotype: Tg(TRAMP)8247Ng/0
involves: 129S1/Sv * C57BL/6

endocrine/exocrine gland phenotype

increased prostate gland tumor incidence

neoplasm

increased prostate gland tumor incidence

reproductive system phenotype

increased prostate gland tumor incidence

The following phenotype relates to a compound genotype created using this strain

Genotype: Tg(TRAMP)8247Ng/0
involves: C57BL/6

endocrine/exocrine gland phenotype

increased prostate gland adenocarcinoma incidence
- mice exhibit a range of prostate hyperplasia to invasive carcinomas
- mice treated with bromhexine hydrochloride, a TMPRSS2 inhibitor, at 15 weeks of age and continued to about 20 weeks, show larger prostate glands (ie, larger prostate tumors) than vehicle-treated mice and reduced incidence of distant metastasis to lung and liver from 55% in vehicle-treated mice to 20% with bromhexine hydrochloride
- males display focal and invasive adenocarcinoma of the prostate by 20 weeks

prostate gland hyperplasia
- intraepithelial hyperplasia can be detected in males by 10 weeks of age and by 22 weeks of age, almost all prostatic glands are hyperplastic

neoplasm

increased prostate gland adenocarcinoma incidence
- males display focal and invasive adenocarcinoma of the prostate by 20 weeks
- mice exhibit a range of prostate hyperplasia to invasive carcinomas
- mice treated with bromhexine hydrochloride, a TMPRSS2 inhibitor, at 15 weeks of age and continued to about 20 weeks, show larger prostate glands (ie, larger prostate tumors) than vehicle-treated mice and reduced incidence of distant metastasis to lung and liver from 55% in vehicle-treated mice to 20% with bromhexine hydrochloride

reproductive system phenotype

increased prostate gland adenocarcinoma incidence
- males display focal and invasive adenocarcinoma of the prostate by 20 weeks
- mice treated with bromhexine hydrochloride, a TMPRSS2 inhibitor, at 15 weeks of age and continued to about 20 weeks, show larger prostate glands (ie, larger prostate tumors) than vehicle-treated mice and reduced incidence of distant metastasis to lung and liver from 55% in vehicle-treated mice to 20% with bromhexine hydrochloride
- mice exhibit a range of prostate hyperplasia to invasive carcinomas

prostate gland hyperplasia
- intraepithelial hyperplasia can be detected in males by 10 weeks of age and by 22 weeks of age, almost all prostatic glands are hyperplastic

References

Greenberg NM; DeMayo F; Finegold MJ; Medina D; Tilley WD; Aspinall JO; Cunha GR; Donjacour AA; Matusik RJ; Rosen JM. 1995. Prostate cancer in a transgenic mouse. Proc Natl Acad Sci U S A 92(8):3439-43PubMed: 7724580 MGI: J:65303
Huss WJ; Maddison LA; Greenberg NM. 2001. Autochthonous mouse models for prostate cancer: past, present and future. Semin Cancer Biol 11(3):245-60PubMed: 11407949 MGI: J:78291

Additional References

Foster BA; Gingrich JR; Kwon ED; Madias C; Greenberg NM. 1997. Characterization of prostatic epithelial cell lines derived from transgenic adenocarcinoma of the mouse prostate (TRAMP) model. Cancer Res 57(16):3325-30PubMed: 9269988 MGI: J:42333
Foster BA; Kaplan PJ; Greenberg NM. 1999. Characterization of the FGF axis and identification of a novel FGFR1iiic isoform during prostate cancer progression in the TRAMP model. Prostate Cancer Prostatic Dis 2(2):76-82PubMed: 12496842 MGI: J:84412
Gingrich JR; Barrios RJ; Foster BA; Greenberg NM. 1999. Pathologic progression of autochthonous prostate cancer in the TRAMP model. Prostate Cancer Prostatic Dis 2(2):70-75PubMed: 12496841 MGI: J:66957
Gingrich JR; Greenberg NM. 1996. A transgenic mouse prostate cancer model. Toxicol Pathol 24(4):502-4PubMed: 8864193 MGI: J:78848
Han G; Foster BA; Mistry S; Buchanan G; Harris JM; Tilley WD; Greenberg NM. 2001. Hormone status selects for spontaneous somatic androgen receptor variants that demonstrate specific ligand and cofactor dependent activities in autochthonous prostate cancer. J Biol Chem 276(14):11204-13PubMed: 11063747 MGI: J:69752
Hsu CX; Ross BD; Chrisp CE; Derrow SZ; Charles LG; Pienta KJ; Greenberg NM; Zeng Z; Sanda MG. 1998. Longitudinal cohort analysis of lethal prostate cancer progression in transgenic mice. J Urol 160(4):1500-5PubMed: 9751403 MGI: J:50294
Hurwitz AA; Foster BA; Kwon ED; Truong T; Choi EM; Greenberg NM; Burg MB; Allison JP. 2000. Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockade. Cancer Res 60(9):2444-8PubMed: 10811122 MGI: J:62479
Huss WJ; Barrios RJ; Foster BA; Greenberg NM. 2003. Differential expression of specific FGF ligand and receptor isoforms during angiogenesis associated with prostate cancer progression. Prostate 54(1):8-16PubMed: 12481250 MGI: J:81095
Huss WJ; Hanrahan CF; Barrios RJ; Simons JW; Greenberg NM. 2001. Angiogenesis and prostate cancer: identification of a molecular progression switch. Cancer Res 61(6):2736-43PubMed: 11289156 MGI: J:68468
Kaplan-Lefko PJ; Chen TM; Ittmann MM; Barrios RJ; Ayala GE; Huss WJ; Maddison LA; Foster BA; Greenberg NM. 2003. Pathobiology of autochthonous prostate cancer in a pre-clinical transgenic mouse model. Prostate 55(3):219-37PubMed: 12692788 MGI: J:83083
Kee K; Foster BA; Merali S; Kramer DL; Hensen ML; Diegelman P; Kisiel N; Vujcic S; Mazurchuk RV; Porter CW. 2004. Activated polyamine catabolism depletes acetyl-CoA pools and suppresses prostate tumor growth in TRAMP mice. J Biol Chem 279(38):40076-83PubMed: 15252047 MGI: J:93350
Kwabi-Addo B; Giri D; Schmidt K; Podsypanina K; Parsons R; Greenberg N; Ittmann M. 2001. Haploinsufficiency of the Pten tumor suppressor gene promotes prostate cancer progression. Proc Natl Acad Sci U S A 98(20):11563-8PubMed: 11553783 MGI: J:71740
Kwon ED; Foster BA; Hurwitz AA; Madias C; Allison JP; Greenberg NM; Burg MB. 1999. Elimination of residual metastatic prostate cancer after surgery and adjunctive cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) blockade immunotherapy Proc Natl Acad Sci U S A 96(26):15074-9PubMed: 10611340 MGI: J:59573
Leman ES; Arlotti JA; Dhir R; Greenberg N; Getzenberg RH. 2002. Characterization of the nuclear matrix proteins in a transgenic mouse model for prostate cancer. J Cell Biochem 86(2):203-12PubMed: 12111990 MGI: J:77969
Mentor-Marcel R; Lamartiniere CA; Eltoum IE; Greenberg NM; Elgavish A. 2001. Genistein in the diet reduces the incidence of poorly differentiated prostatic adenocarcinoma in transgenic mice (TRAMP). Cancer Res 61(18):6777-82PubMed: 11559550 MGI: J:71655
Schatten H; Wiedemeier AM; Taylor M; Lubahn DB; Greenberg NM; Besch-Williford C; Rosenfeld CS; Day JK; Ripple M. 2000. Centrosome-centriole abnormalities are markers for abnormal cell divisions and cancer in the transgenic adenocarcinoma mouse prostate (TRAMP) model. Biol Cell 92(5):331-40PubMed: 11071042 MGI: J:65344
Shih SC; Robinson GS; Perruzzi CA; Calvo A; Desai K; Green JE; Ali IU; Smith LE; Senger DR. 2002. Molecular profiling of angiogenesis markers. Am J Pathol 161(1):35-41PubMed: 12107087 MGI: J:77978
Wechter WJ; Leipold DD; Murray ED Jr; Quiggle D; McCracken JD; Barrios RS; Greenberg NM. 2000. E-7869 (R-flurbiprofen) inhibits progression of prostate cancer in the TRAMP mouse Cancer Res 60(8):2203-8PubMed: 10786685 MGI: J:61729

Additional - Tg(TRAMP)8247Ng related

Technical Support

CONTACT TECHNICAL SUPPORT

Genotyping Protocols
- Standard PCR:Tg(TRAMP)8247Ng
- Standard PCR:Tg(TRAMP)8247Ng-Chr16
- Genotyping resources and troubleshooting
Dietary Information
- LabDiet® 5K52 formulation (6% fat)
Breeding Considerations

When maintaining our live colony, C57BL/6J inbred mice are bred to hemizygous mice. Most commonly, but not exclusively, this is C57BL/6J females bred to hemizygous males. Expected coat color from breeding is black. [2020]
- Additional Breeding and Husbandry Support
Mating System
- C57BL/6J (000664) x Hemizygote
- Hemizygous x C57BL/6J (000664)
Appearance
- black
  Related Genotype: a/a
Citation
When using the B6 TRAMP mice mouse strain in a publication, please cite the originating article(s) and include JAX stock #003135 in your Materials and Methods section.

Animal Health Reports

Facility Barrier Level Descriptions

AX11 (Maximum)

Pricing & Availability

Available

Domestic
International

Live Mouse

Age

Genotype

Price

weeks

Breeder Pair

Sex

Genotype

Price

Female
Male

Cryorecovery - Pricing

Service/Product	Description	Price
> >	Hemizygous or Non carrier for Tg(TRAMP)8247Ng

Payment Terms and Conditions

Terms are granted by individual review and stated on the customer invoice(s) and account statement. These transactions are payable in U.S. currency within the granted terms. Payment for services, products, shipping containers, and shipping costs that are rendered are expected within the payment terms indicated on the invoice or stated by contract. Invoices and account balances in arrears of stated terms may result in The Jackson Laboratory pursuing collection activities including but not limited to outside agencies and court filings.

The Jackson Laboratory's Genotype Promise

The Jackson Laboratory has rigorous genetic quality control and mutant gene genotyping programs to ensure the genetic background of JAX® Mice strains as well as the genotypes of strains with identified molecular mutations. JAX® Mice strains are only made available to researchers after meeting our standards. However, the phenotype of each strain may not be fully characterized and/or captured in the strain data sheets. Therefore, we cannot guarantee a strain's phenotype will meet all expectations. To ensure that JAX® Mice will meet the needs of individual research projects or when requesting a strain that is new to your research, we suggest ordering and performing tests on a small number of mice to determine suitability for your particular project. We do not guarantee breeding performance and therefore suggest that investigators order more than one breeding pair to avoid delays in their research.

Terms Of Use

General Terms and Conditions

Questions about Terms of Use

Additional Use Restrictions Apply

Use of MICE by companies or for-profit entities requires a license prior to shipping.

Licensing Information

Phone: 207-288-6470

Email: TechTran@jax.org

Also Known As:B6 TRAMP mice

Donating Investigator

Genetic overview

Research Applications

Base Price

Detailed Description

Development

Expression Data

Control Suggestions

Additional Information

Selected References

Tg(TRAMP)8247Ng

Allele Symbol: Tg(TRAMP)8247Ng

Disease Terms

Characteristics of this human disease are associated with transgenes and other mutation types in the mouse.

Research Areas By Phenotype

This mouse can be used to support research in many areas including:

Mammalian Phenotype Terms by Genotype

Genotype: Tg(TRAMP)8247Ng/0involves: 129/Sv * C57BL/6

endocrine/exocrine gland phenotype

reproductive system phenotype

neoplasm

Genotype: Tg(TRAMP)8247Ng/0involves: C3H * C57BL/6

endocrine/exocrine gland phenotype

neoplasm

reproductive system phenotype

Genotype: Tg(TRAMP)8247Ng/0involves: 129S1/Sv * C57BL/6

endocrine/exocrine gland phenotype

neoplasm

reproductive system phenotype

Genotype: Tg(TRAMP)8247Ng/0involves: C57BL/6

endocrine/exocrine gland phenotype

neoplasm

reproductive system phenotype

References

Additional References

Additional - Tg(TRAMP)8247Ng related

Genotyping Protocols

Dietary Information

Breeding Considerations

Mating System

Appearance

Citation

Animal Health Reports

Live Mouse

Breeder Pair

Cryorecovery - Pricing

Payment Terms and Conditions

The Jackson Laboratory's Genotype Promise

Terms Of Use

Additional Use Restrictions Apply

Licensing Information

Genotype: Tg(TRAMP)8247Ng/0
involves: 129/Sv * C57BL/6

Genotype: Tg(TRAMP)8247Ng/0
involves: C3H * C57BL/6

Genotype: Tg(TRAMP)8247Ng/0
involves: 129S1/Sv * C57BL/6

Genotype: Tg(TRAMP)8247Ng/0
involves: C57BL/6